Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria

Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?

(2013) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure

(2013) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Frequency offksMutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method

(2013) M. A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination viaIn VivoPharmacodynamic Evaluation against Candida glabrata with and withoutfksMutations

(2012) Alexander Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

(2012) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

(2012) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*

(2012) Maiken C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type andfksHot Spot Mutant Candida Isolates

(2011) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin

(2011) J. L. Slater et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandin Susceptibility Testing ofCandidaspp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots

(2011) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata

(2011) Elisabetta Spreghini et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

(2010) M. Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

(2010) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing

(2008) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY